Welcome to our dedicated page for CapsoVision news (Ticker: CV), a resource for investors and traders seeking the latest updates and insights on CapsoVision stock.
CapsoVision, Inc. (NASDAQ: CV) is a commercial-stage medical technology company that regularly issues news and updates related to its advanced imaging and AI-enabled capsule endoscopy solutions for gastrointestinal disease detection. This news page aggregates company press releases and market announcements so readers can follow developments around its medical devices and regulatory progress.
CapsoVision’s news flow often covers topics such as performance of its flagship CapsoCam Plus capsule endoscopy system for small bowel visualization, including adoption trends and usage metrics disclosed in quarterly financial results. The company also reports on regulatory milestones, for example submissions of 510(k) applications to the U.S. Food and Drug Administration for its AI-assisted reading module for CapsoCam Plus and for CapsoCam Colon, a capsule designed for non-invasive colon imaging and polyp detection.
Investors and healthcare professionals can also find updates on CapsoVision’s efforts to expand its capsule platform into new indications. These include its application for Breakthrough Device Designation for the CapsoCam UGI capsule endoscopy system for potential early-stage pancreatic cancer detection, as well as broader plans to address multiple GI indications, including esophageal and pancreatic disorders.
In addition, CapsoVision uses news releases to communicate quarterly financial results, participation in investor conferences, and changes in its leadership team, such as executive appointments and transitions. By reviewing the items on this page, readers can track how CapsoVision is advancing its AI-enabled capsule endoscopy portfolio, progressing through regulatory pathways, and managing its public company responsibilities. For ongoing insight into CV-related announcements, this page provides a centralized view of the company’s official news.
CapsoVision (NASDAQ: CV), a commercial-stage medical technology company specializing in advanced imaging and AI-powered capsule endoscopy solutions, has scheduled its second quarter 2025 financial results release for Thursday, August 14, 2025, after market close.
The company will host a conference call and live webcast at 4:30 PM ET on the same day. Investors can access the call by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with conference ID 1668374. A webcast will be available in the investor relations section of CapsoVision's website.
CapsoVision (NASDAQ: CV), a medical technology company specializing in capsule endoscopy solutions with advanced imaging and AI technologies, has successfully completed its Initial Public Offering (IPO). The company offered 5.5 million shares at $5.00 per share, raising gross proceeds of $27.5 million.
Trading commenced on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The underwriters, The Benchmark Company and Roth Capital Partners, have a 30-day option to purchase up to 825,000 additional shares at the IPO price, less underwriting discounts and commissions.
CapsoVision (NASDAQ: CV), a commercial-stage medical technology company specializing in advanced imaging and AI-powered capsule endoscopy solutions, has announced the pricing of its initial public offering (IPO). The company is offering 5,500,000 shares of common stock at $5.00 per share.
Trading is set to commence on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The offering, expected to close on July 3, 2025, aims to raise approximately $27.5 million in gross proceeds before deducting underwriting costs and other expenses. The underwriters have a 30-day option to purchase up to 825,000 additional shares at the IPO price.
The Benchmark Company and Roth Capital Partners are serving as joint book-running managers for the offering, which will be conducted through a prospectus as part of an SEC-approved registration statement.